This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Moons, L. Articles by Rapold, H. J. Search for Related Content PubMed PubMed Citation Articles by Moons, L. Articles by Rapold, H. J. Social Bookmarking                         What's this?

Toxicology Studies with Recombinant Staphylokinase and with SY 161-P5, a Polyethylene Glycol-Derivatized Cysteine-Substitution Mutant

Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, KU Leuven, Belgium

Ingrid Vanlinthout

Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, KU Leuven, Belgium

Ivo Roelants

Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, KU Leuven, Belgium

Randall Moreadith

ThromboGenics Ltd, Dublin, Ireland

Desire Collen

Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, KU Leuven, Belgium, desire.collen{at}med.kuleuven.ac.be, ThromboGenics Ltd, Dublin, Ireland

Hans J. Rapold

ThromboGenics Ltd, Dublin, Ireland

SY161-P5, a polyethylene glycol derivatized (PEGylated) mutant of the recombinant Staphylokinase (rSak) variant SakSTAR, exhibiting reduced antigenicity, is in clinical development for treatment of acute myocardial infarction as a single bolus injection. A series of safety studies were performed in vivo as a routine toxicology program with SY 161-P5 (PEG-rSakSTAR) and with the recombinant Staphylokinase variant Sak42D (rSak42D). For both compounds, intravenous single bolus injections of up to 100-fold therapeutic equivalent, as well as repeated injections during 7 to 28 days revealed no significant pathological findings in mice, rats or hamsters. However, New Zealand white rabbits developed clinically silent, multifocal myocarditis following single or repeat doses of SY 161-P5 or of Sak42D. These findings were dose-independent and reversible. A similar speciesspecific cardiotoxic effect has previously been described for other proteolytic proteins, including the approved drugs Streptokinase and Acetylated Plasminogen Streptokinase Complex (APSAC). The large experience with these drugs, as well as the clinical data accumulated both with PEGylated and non-PEGylated rSak variants to date, do not indicate cardiotoxic hazards associated with the use of these drugs in humans.

Key Words: Myocardial infarction • myocarditis • thrombolysis • rabbit • rat • hamster

References

• AIMS Trial Study Group ( 1988 ). Effect of intravenous APSAC on mortality after acute myocardial infarction: Preliminary report of a placebo-controlled clinical trial. Lancet i: 545—549.
• Artus JA, Cockburn A., Fuller J., McMurdo AS, White DJ (1987). The pre-clinical Toxicology of Anisoylated Plasminogen Streptokinase Activator Complex. Drugs 33 (Suppl 3): 97—101.
• Assessment of the Safety and Efficacy of a New Thrombolytic (Assent-2) Investigators (1999). Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: The ASSENT-2 double blind randomised trial. Lancet 354: 716—722.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Coan MJ, Giddens W., Ellis W., Reichenbach DD (1983). Selective myocardial cell necrosis in non-human primates. Arch Pathol Lab Med 107: 34—39.[Web of Science][Medline] [Order article via Infotrieve]
• Collen D., Sinnaeve P., Demarsin E., Moreau H., De Maeyer M., Jespers L., Laroche Y., Van de Werf F. (2000). Polyethylene glycol-derivatized cysteine-substitution variants of recombinant staphylokinase for single bolus treatment of acute myocardial infarction. Circulation 102: 1766—1772.[Abstract/Free Full Text]
• Collen D., Van de Werf F. (1993). Coronary thrombolysi s with recombinant staphylokinas e in patients with evolving myocardial infarction. Circulation 87: 1850—1853.[Abstract/Free Full Text]
• Collen D., Van Hoef B., Schlott B., Hartmann M., Guehrs KH, Lijnen HR (1993). Mechanisms of activation of mammalian plasma fibrinolytic systems with streptokinase and with recombinant staphylokinase. Eur J Biochem 216: 307—314.[Web of Science][Medline] [Order article via Infotrieve]
• Collen D. (1996). Fibrin-selective thrombolytic therapy for acute myocardial infarction. Circulation 93: 857—865.[Free Full Text]
• Collen D., Moreau H., Stockx L., Vanderschueren S. (1996). Recombinant staphylokinase variants with altered immunoreactivity II: Thrombolytic properties and antibody induction. Circulation 94: 207—216.[Abstract/Free Full Text]
• Collen D. (1998). Staphylokinase: a potent, uniquely fibrin-selective thrombolytic agent. Nature Med 4: 279—284.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Collen D. (1999). The plasminogen (fibrinolytic) system. Thromb Haemost 82: 259—270.[Web of Science][Medline] [Order article via Infotrieve]
• Declerck PJ, Vanderschueren S., Billiet J., Moreau H., Collen D. (1994). Prevelance and induction of circulating antibodies against recombinant staphylokinase. Thromb Haemost 71: 129—133.[Web of Science][Medline] [Order article via Infotrieve]
• Di Muzio A. (1997). Inflammatory myopathy after intravenous Streptokinase. Muscle Nerve 20: 619—621.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Gruppo Italiano per lo Studio della Sterptochinasi nell' Infarto Miocardico (GISSI) (1987). Long-term effects of intravenous thrombolysis in acute myocardial infarction: final report of the GISSI study. Lancet ii: 871— 874.
• Gulba DC, Praus M., Dechend R., Hauck S., Mahler M., Zitvz R., Baldus B., Mueller W., Dietz R. (1997). Update on the toxicology and pharmacology of rDSPA alpha 1 (bat-PA) in animals and humans. Fibrinol Proteol 11(Suppl 2): 55—62.
• ISIS-2 (Second International Study of Infarct Survival) Collaborative group (1988). Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet ii: 349—360.
• Kellner A., Robertson T. (1954). Selective necrosis of cardiac and skeletal muscle induced experimentally by means of proteolytic enzyme solutions given intravenously. J Exp Med 99: 387—403.[Abstract/Free Full Text]
• Laroche Y., Heymans S., Capaert S., De Cock F., Demarsin E., Collen D. (2000). Recombinant Staphylokinas e variants with reduced antigenicity due to elimination of B-lymphocyte epitopes. Blood 96: 1425—1432.[Abstract/Free Full Text]
• Lijnen HR, De Cock F., Matsuo O., Collen D. (1992). Comparative fibrinolytic and fibrinogenolytic properties of staphylokinase and streptokinase in plasma of different species in vitro. Fibrinolysis 6: 33—37.
• Mattheussen M., Mubagwa K., Rusy BF, Van Aken H., Flameng D. (1993). Potentiated state contractions in isolated hearts: Effects of ischemia and reperfusion. Am J Physiol 264: H1663—H1673.[Web of Science][Medline] [Order article via Infotrieve]
• Reichenbach DD, Benditt EP (1970). Catecholamine s and cardiomyopathy. The pathogenesi s and potential importance of myofibrillar degeneration. Human Pathol 1: 125—150.[CrossRef]
• Schlott B., Guehrs KH, Hartmann M., Roecker A., Collen D. (1997). Staphylokinase requires NH2-terminal proteolysis for plasminogen activation. J Biol Chem 272: 6067—6072.[Abstract/Free Full Text]
• Schlott B., Hartmann M., Gührs KH, Birch-Hirschfeld E., Pohl HD, Vanderschueren S., Van de Werf F., Michoel A., Collen D., Behnke D. (1994). High yield production and purification of recombinant staphylokinase for thrombolytic therapy. BioTechnology 12: 185—189.[CrossRef][Medline] [Order article via Infotrieve]
• The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators (1997). A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med 337: 1118—1123.[Abstract/Free Full Text]
• Vanderschueren S., Barrios L., Kerdsinchai P., Van den Heuvel P., Hermans L., Vrolix M., De Man F., Benit E., Muyldermans L., Collen D., Van de Werf F. (1995). A randomized trial of recombinant staphylokinase versus alteplase for coronary artery patency in acute myocardial infarction. The STAR Trial Group. Circulation 92: 2044—2049.[Abstract/Free Full Text]
• Vanderschueren S., Dens J., Kerdsinchai P., Desmet W., Vrolix M., De Man F., Van den Heuvel P., Hermans L., Collen D., Van de Werf F. (1997). A pilot randomized coronary patency trial of double-bolus recombinant staphylokinase versus front-loaded alteplase in acute myocardial infarction. Am Heart J 134: 213—219.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Vanwetswinkel S., Plaisance S., Zhang Z., Valinhout I., Brepoels K., Lasters I., Collen D., Jespers L. (2000). Pharmacokinetic and thrombolytic properties of cystein-linked polyethylene glycol derivatives of staphylokinase. Blood 95: 936—942.[Abstract/Free Full Text]

Toxicologic Pathology, Vol. 29, No. 3, 285-291 (2001)
DOI: 10.1080/019262301316905237


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Moons, L. Articles by Rapold, H. J. Search for Related Content PubMed PubMed Citation Articles by Moons, L. Articles by Rapold, H. J. Social Bookmarking                         What's this?